Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Breast Neoplasms 61Neoplasm Metastasis 6Neoplasms 4Endometrial Neoplasms 4Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Ovarian Neoplasms 2Neuroblastoma 2Neoplasms by Site 2Melanoma 2Hereditary Sensory and Autonomic Neuropathies 2Glioma 2Glioblastoma 2Carcinoma, Ovarian Epithelial 2Breast Diseases 2Anatomic Stage II Breast Cancer AJCC v8 2Venous Thromboembolism 1Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Sarcoma 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Meningioma 1

Interventions

Cisplatin 26Paclitaxel 21pembrolizumab 15Radiotherapy 13Carboplatin 13tislelizumab 12Fluorouracil 12Drug Therapy 11Irinotecan 9toripalimab 8Esophagectomy 8Oxaliplatin 6Nivolumab 6Capecitabine 6Neoadjuvant Therapy 5Leucovorin 5Docetaxel 5lenvatinib 4camrelizumab 4Taxes 4Radiation 4Levoleucovorin 4Immune Checkpoint Inhibitors 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4spartalizumab 3sintilimab 3apatinib 3Itraconazole 3Injections 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Squamous Cell Carcinoma × ribociclib × 1 year × Clear all
NCT04000529 2025-09-30

Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

Novartis

Phase 1 Terminated
122 enrolled
GastrointestinalHead & NeckSarcomaThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡